{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-006089","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.569540+00:00","generated_at":"2026-05-30T03:14:59.234390+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cassava Sciences reports Q3 net loss $27.9M; RETHINK-ALZ top-line data expected by end-2024","bullets":["Net loss $27.9M ($0.58 per share) vs $25.7M ($0.61) in Q3 2023; cash $149M at Sep 30, 2024.","Top-line results from Phase 3 RETHINK-ALZ trial (simufilam) expected before end of 2024.","DSMB recommended both Phase 3 studies continue as planned at Sep 2024 meeting.","Year-end 2024 cash estimated $117-127M; $40M SEC settlement in escrow excluded.","Open-label extension study enrolled over 1,040 patients; 88% opt-in rate."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-006089","json":"https://secwatch.observer/filing/0001171843-24-006089.json","markdown":"https://secwatch.observer/filing/0001171843-24-006089.md","text":"https://secwatch.observer/filing/0001171843-24-006089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324006089/0001171843-24-006089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184324006089/f8k_110724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:14:59.234390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}